Erythema multiforme adverse event reports that record this term

Kind of term: MedDRA preferred term
Plain meaning: a skin reaction with target-shaped patches

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 9,143 adverse event reports that record the MedDRA preferred term Erythema multiforme. In plain words, the term means: a skin reaction with target-shaped patches. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 481 reports in the 12 months to June 2026 and 515 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,008 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 481 (under 0.1%) record this term. Reports for patients aged 45 to 64 were 27.4% of the reports that record this term and 20% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

A skin reaction with target-shaped patches. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 103 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Erythema multiforme name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		137
Acetylsalicylic Acid		29
Allopurinol	Xanthine oxidase inhibitor	178
Amoxicillin	Penicillin-class antibacterial	154
Aspirin	Nonsteroidal anti-inflammatory drug	82
Atezolizumab	Programmed death Receptor-1 blocking antibody	51
Augmentin	Penicillin-class antibacterial	29
Augmentin '125		28
Avastin	Vascular endothelial growth factor inhibitor	71
Azithromycin	Macrolide antimicrobial	29
Azithromycin Anhydrous		29
Bevacizumab	Vascular endothelial growth factor inhibitor	61
Bextra		60
Bisoprolol	beta-Adrenergic blocker	31
Carbamazepine	Mood stabilizer	87
Carboplatin	Platinum-based drug	171
Ceftriaxone	Cephalosporin antibacterial	43
Celebrex	Nonsteroidal anti-inflammatory drug	25
Celecox		40
Celecoxib	Nonsteroidal anti-inflammatory drug	28
Cetirizine hydrochloride	Histamine-1 receptor antagonist	32
Ciprofloxacin	Fluoroquinolone antibacterial	48
Cisplatin	Platinum-based drug	43
Clarithromycin	Macrolide antimicrobial	118
Clindamycin	Lincosamide antibacterial	25
Crestor	HMG-CoA reductase inhibitor	28
Cyclophosphamide	Alkylating drug	59
Dexamethasone	Corticosteroid	55
Diclofenac	Nonsteroidal anti-inflammatory drug	40
Diclofenac sodium	Nonsteroidal anti-inflammatory drug	57
Dilantin	Anti-epileptic agent	27
Diltiazem		25
Diovan	Angiotensin 2 receptor blocker	26
Docetaxel	Microtubule inhibitor	36
Dupixent	Interleukin-4 receptor alpha antagonist	44
Enbrel	Tumor necrosis factor blocker	61
Enfortumab vedotin		34
Faslodex	Estrogen receptor antagonist	46
Fluconazole	Azole antifungal	65
Fluorouracil	Nucleoside metabolic inhibitor	44
Fulvestrant	Estrogen receptor antagonist	29
Furosemide	Loop diuretic	37
Humira		58
Hydrocortisone	Corticosteroid	28
Hydroxychloroquine	Antimalarial	52
Ibuprofen	Nonsteroidal anti-inflammatory drug	260
Ipilimumab	CTLA-4-directed blocking antibody	43
Keytruda	Programmed death Receptor-1 blocking antibody	156
Lamictal	Anti-epileptic agent	206
Lamisil		25
Lamotrigine	Anti-epileptic agent	151
Lansoprazole	Proton pump inhibitor	51
Lenvima	Kinase inhibitor	43
Levetiracetam		33
Levofloxacin	Fluoroquinolone antibacterial	41
Lyrica		85
Metformin	Biguanide	27
Methotrexate	Folate analog metabolic inhibitor	66
Metronidazole	Nitroimidazole antimicrobial	36
Nemolizumab		54
Nexavar	Kinase inhibitor	86
Nexium	Proton pump inhibitor	27
Nitroglycerin	Nitrate vasodilator	33
Nivolumab	Programmed death Receptor-1 blocking antibody	86
Omeprazole	Proton pump inhibitor	66
Opdivo	Programmed death Receptor-1 blocking antibody	148
Oxaliplatin	Platinum-based drug	31
Paclitaxel	Microtubule inhibitor	165
Paracetamol		46
Pegasys	Interferon alpha	28
Peginterferon Alfa-2b		46
Pegintron		94
Pembrolizumab	Programmed death Receptor-1 blocking antibody	84
Pemetrexed	Folate analog metabolic inhibitor	34
Phenytoin	Anti-epileptic agent	89
Prednisolone	Corticosteroid	59
Prednisone	Corticosteroid	64
Ramipril	Angiotensin converting enzyme inhibitor	41
Ranitidine	Histamine-2 receptor antagonist	35
Rebetol		116
Remicade	Tumor necrosis factor blocker	48
Revlimid	Thalidomide analog	57
Ribavirin	Nucleoside analog antiviral	67
Rituximab	CD20-directed cytolytic antibody	60
Rocephin		26
Sertraline	Serotonin reuptake inhibitor	52
Sulfamethoxazole and trimethoprim	Dihydrofolate reductase inhibitor antibacterial	43
Sulfamethoxazole, trimethoprim	Dihydrofolate reductase inhibitor antibacterial	36
Tagrisso	Kinase inhibitor	39
Tamiflu	Neuraminidase inhibitor	30
Tecentriq	Programmed death Receptor-1 blocking antibody	55
Tegretol	Mood stabilizer	107
Telavic		108
Terbinafine	Allylamine antifungal	33
Tislelizumab		40
Truqap		66
Vancomycin	Glycopeptide antibacterial	98
Vancomycin hydrochloride	Glycopeptide antibacterial	32
Velcade	Proteasome inhibitor	34
Vemurafenib	Kinase inhibitor	42
Vincristine		26
Vx-950		78
Yervoy	CTLA-4-directed blocking antibody	82

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 41 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Erythema multiforme name, in order of name
Class	Reports with this term
Alkylating drug	87
Angiotensin 2 receptor blocker	67
Angiotensin converting enzyme inhibitor	58
Anti-epileptic agent	567
Antimalarial	90
Atypical antipsychotic	101
Azole antifungal	84
Benzodiazepine	59
beta-Adrenergic blocker	55
CD20-directed cytolytic antibody	71
Cephalosporin antibacterial	107
Corticosteroid	290
CTLA-4-directed blocking antibody	137
Dihydrofolate reductase inhibitor antibacterial	103
Estrogen receptor antagonist	75
Factor Xa inhibitor	60
Fluoroquinolone antibacterial	94
Folate analog metabolic inhibitor	114
Glycopeptide antibacterial	130
Histamine-1 receptor antagonist	69
HMG-CoA reductase inhibitor	98
Kinase inhibitor	514
Loop diuretic	57
Macrolide antimicrobial	162
Microtubule inhibitor	212
Mood stabilizer	197
Nitrate vasodilator	51
Nonsteroidal anti-inflammatory drug	563
Nucleoside analog antiviral	67
Nucleoside metabolic inhibitor	128
P2Y12 platelet inhibitor	56
Penicillin-class antibacterial	218
Platinum-based drug	245
Programmed death Receptor-1 blocking antibody	580
Proteasome inhibitor	55
Proton pump inhibitor	204
Serotonin reuptake inhibitor	104
Thalidomide analog	76
Tumor necrosis factor blocker	154
Vascular endothelial growth factor inhibitor	134
Xanthine oxidase inhibitor	185

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Erythema multiforme, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Erythema multiforme
Age	Reports	Share
Under 2	109	1.2%
2 to 11	304	3.3%
12 to 17	199	2.2%
18 to 44	1,557	17%
45 to 64	2,502	27.4%
65 to 74	1,560	17.1%
75 and over	1,209	13.2%
Age not given	1,703	18.6%

Sex of the patient in the reports that record Erythema multiforme
Sex	Reports	Share
Female	4,627	50.6%
Male	3,672	40.2%
Unknown or not given	844	9.2%

Age and sex are as the report gives them. 18.5% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Erythema multiforme: adverse event reports that record this term. https://reportedreactions.com/reaction/erythema-multiforme/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Erythema multiforme mean in an adverse event report?

In plain words: a skin reaction with target-shaped patches. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page